Why the study?
Does the publication of the MATCH trial reduce the frequency of discharge prescription of aspirin+clopidogrel in patients with ischemic stroke or TIA?
Does the publication of the MATCH trial reduce the frequency of discharge prescription of aspirin+clopidogrel in patients with ischemic stroke or TIA?
The publication of the MATCH trial led to a rapid and sustained reduction in the discharge prescription of aspirin plus clopidogrel for ischemic stroke and TIA, demonstrating that clinical trial results can rapidly change real-world prescribing behavior.
Answers are grounded in this paper and cite their sources.
MATCH publication was associated with reduced DAPT discharge prescriptions; supports trial results rapidly influencing real-world prescribing patterns.
BACKGROUND AND PURPOSE: Physician prescribing patterns change slowly despite published randomized trials and consensus guidelines. We measure the effect of Management of Atherothrombosis With Clopidogrel in High-Risk Patients (MATCH) trial on discharge prescribing patterns for patients with stroke and those with transient ischemic attack in the Get With The Guidelines (GWTG)-Stroke Program. METHODS: We analyzed discharge prescribing patterns of antithrombotic medications for patients admitted with ischemic stroke or transient ischemic attack at hospitals participating in GWTG-Stroke between October 2002 to January 2006. Clinical information by quarter was analyzed in relation to publication of the MATCH study. Frequency of discharge prescription of aspirin+clopidogrel post-MATCH publication was compared with the pre-MATCH period after adjusting for patient and hospital characteristics and clustering by hospital. RESULTS: A total of 107 872 patients at 632 sites were eligible to receive antithrombotic therapy at discharge. Use of aspirin+clopidogrel therapy declined from 22.4% to 15.4% of patients after the publication of MATCH (adjusted OR 0.62, 95% CI 0.56 to 0.70, P<0.0001). Analysis by quarter revealed a rapid and sustained decrease in use of aspirin+clopidogrel therapy for the remainder of the study period. CONCLUSIONS: A rapid and sustained reduction in the frequency of aspirin+clopidogrel use in ischemic stroke and transient ischemic attack was observed after publication of the MATCH trial in the absence of MATCH-specific GWTG-Stroke initiatives and preceding an American Heart Association guideline update.
No takes yet. Share an insight, caveat, or question.
Menon et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: